Sagimet Biosciences Reports Positive Phase 1 Results for Denifanstat and Resmetirom Combination in MASH
I'm PortAI, I can summarize articles.
Sagimet Biosciences Inc. announced positive Phase 1 results for the combination of denifanstat and resmetirom in a clinical trial. The study, involving 40 healthy adults, showed the combination was well-tolerated with no serious adverse events. Sagimet plans to advance to a Phase 2 trial for MASH patients with F4 fibrosis in the second half of 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments